Does Rallies show Form 4 insider transactions for MAZE?

Yes. Rallies tracks MAZE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is MAZE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MAZE. It does not provide personalized investment advice.

MAZE (Maze Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Maze Therapeutics, Inc. Common Stock (MAZE) is a publicly traded Healthcare sector company. As of May 21, 2026, MAZE trades at $25.03 with a market cap of $1.36B and a P/E ratio of -9.98. MAZE moved +2.37% today. Year to date, MAZE is -35.21%; over the trailing twelve months it is +147.58%. Its 52-week range spans $6.71 to $53.65. Analyst consensus is strong buy with an average price target of $63.50. Rallies surfaces MAZE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading MAZE stock inside the company?

Recent MAZE insider activity includes Coloma Jason V sold 1.82K, Coloma Jason V sold 116, Bernstein Harold sold 15.00K, Dandekar Atul sold 7.50K, and Bernstein Harold sold 11.35K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

MAZE Key Metrics

Key financial metrics for MAZE
Metric	Value
Price	$25.03
Market Cap	$1.36B
P/E Ratio	-9.98
EPS	$-2.48
Dividend Yield	0.00%
52-Week High	$53.65
52-Week Low	$6.71
Volume	0
Avg Volume	0
Revenue (TTM)	$20.00M
Net Income	$-122.54M
Gross Margin	0.00%

Recent MAZE Insider Trades

Coloma Jason V sold 1.82K (~$47.37K) on May 15, 2026.
Coloma Jason V sold 116 (~$3.02K) on May 15, 2026.
Bernstein Harold sold 15.00K (~$393.35K) on May 14, 2026.
Dandekar Atul sold 7.50K (~$190.30K) on Apr 29, 2026.
Bernstein Harold sold 11.35K (~$331.95K) on Apr 1, 2026.

Latest MAZE News

Maze Therapeutics Secures $150M Financing to Fund Pipeline Through 2029 — Apr 22, 2026
Maze’s MZE829 Cuts Proteinuria 35.6%, Moves to Pivotal Trials as Stock Falls 18.3% — Mar 25, 2026
Maze Therapeutics Eyes 30% UACR Reduction in MZE829 and >40-Fold MZE782 Biomarker Rise — Feb 14, 2026

MAZE Analyst Consensus

12 analysts cover MAZE: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $63.50.

Common questions about MAZE

Who is trading MAZE stock inside the company?: Recent MAZE insider activity includes Coloma Jason V sold 1.82K, Coloma Jason V sold 116, Bernstein Harold sold 15.00K, Dandekar Atul sold 7.50K, and Bernstein Harold sold 11.35K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for MAZE?: Yes. Rallies tracks MAZE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is MAZE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MAZE. It does not provide personalized investment advice.